Paliperidone (as palmitate) 1092mg/3.5mL, 1560mg/5mL; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

Johnson & Johnson has had little trouble keeping sales from its Invega portfolio of long-acting antipsychotic injectables in the billions. Now, it's angling for approval of an even more durable ...

Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...

The word "blockbuster" gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat ...

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...

Invega Hafyera (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia. It’s given as an injection into your muscle by your doctor or another healthcare professional. Invega ...